Dotquant specializes in developing advanced biologics such as RNA chimeras and cell therapy engagers for the treatment of cancer and neurological disorders. Our unique and proprietary platforms offer an all-in-one solution to the screening and validation of RNA-based drug candidates, synthesis of chemically modified, stable, long-circulating RNAs at low cost, and targeted delivery in vitro and in vivo.

 

With its roots in research conducted at the University of Washington and with the support of UW CoMotion, Dotquant was launched in 2013 with a mission to connect the dots for future medicine through boundless innovation.